InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
Fierce Pharma

After scrapped trial, InflaRx could tap partner to revive development of COVID drug in rare skin disorder

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
Healio

First patient dosed in phase 3 vilobelimab trial for pyoderma gangrenosum

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...

InflaRx Reopens Case For Axed Phase 3 Drug For Rare Skin Disorder

InflaRx presented data analyses from a terminated Phase 3 study on the potential treatment for rare skin condition.
TipRanks on MSN

InflaRx outlines data analyses of Phase 3 study for vilobelimab in PG

InflaRx (IFRX) outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this ...

InflaRx N.V.: InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...